List of Excipients in Branded Drug CILOXAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	CILOXAN	ciprofloxacin hydrochloride	0065-0654	MINERAL OIL
Alcon Laboratories Inc	CILOXAN	ciprofloxacin hydrochloride	0065-0654	PETROLATUM
Alcon Laboratories Inc	CILOXAN	ciprofloxacin hydrochloride	0065-0656	ACETIC ACID

Ciloxan Excipient Strategy, Patent Status, and Commercial Opportunities

Last updated: September 24, 2026

Ciloxan is a legacy ophthalmic ciprofloxacin product marketed as a 0.3% solution and 0.3% ointment. Its core formulation technology is mature, and the original product exclusivity has expired. Commercial opportunities therefore depend on excipient-led differentiation, preservative-free delivery, improved ocular retention, supply reliability, and regulatory positioning rather than protection of ciprofloxacin itself.

The most commercially relevant product concepts are preservative-free unit-dose drops, higher-retention multidose systems, improved ointment vehicles, and combination products that address adherence or broader ocular-surface needs. Generic entry risk is high for the conventional 0.3% solution because the active ingredient, strength, dosage form, and administration route are well established.

What is Ciloxan and which dosage forms are marketed?

Ciloxan contains ciprofloxacin hydrochloride, equivalent to ciprofloxacin 0.3% w/v. It is an ophthalmic fluoroquinolone antibiotic used for bacterial conjunctivitis and corneal ulcers caused by susceptible organisms. The product is available in two primary dosage forms:

Product	Strength	Dosage form	Principal use
Ciloxan ophthalmic solution	0.3%	Sterile aqueous eye drops	Bacterial conjunctivitis and corneal ulcer
Ciloxan ophthalmic ointment	0.3%	Sterile ophthalmic ointment	Bacterial ocular infections

The ophthalmic solution is dosed frequently during initial treatment, particularly for corneal ulcers. The label allows pediatric use in patients aged one year and older. Ciprofloxacin ophthalmic products are generally approved through abbreviated or hybrid generic pathways depending on the product and jurisdiction. They are not biologics and do not create biosimilar issues.

What excipients are used in Ciloxan ophthalmic solution?

The Ciloxan solution uses a relatively simple aqueous excipient system. The FDA labeling identifies the following inactive ingredients:

Excipient	Functional role
Boric acid	Buffering and tonicity contribution
Sodium chloride	Tonicity adjustment
Edetate disodium	Chelating agent; supports preservative and formulation stability where applicable
Hydrochloric acid and/or sodium hydroxide	pH adjustment
Purified water	Vehicle

The labeled product has an acidic formulation, with a reported pH of approximately 4.5. The formulation is designed to maintain ciprofloxacin solubility and chemical stability while remaining suitable for ocular administration. Ciprofloxacin has limited aqueous solubility at neutral pH, so pH control is a central formulation variable.

The absence of a conventional antimicrobial preservative in the listed excipient system is commercially relevant. A preservative-free profile can support positioning for patients with chronic ocular-surface disease, frequent dosing, contact-lens intolerance, or sensitivity to benzalkonium chloride. It also reduces one potential source of epithelial toxicity, although sterile packaging and container integrity become more important.

What excipients are used in Ciloxan ophthalmic ointment?

The ointment uses a conventional anhydrous hydrocarbon base:

Excipient	Functional role
Mineral oil	Lubricity and vehicle
White petrolatum	Semisolid base and ocular retention

The ointment base extends residence time on the ocular surface compared with an aqueous drop. Its main disadvantages are temporary blurred vision, less convenient administration, and lower patient acceptance for daytime use. These characteristics create room for differentiated semisolid systems using less visually disruptive vehicles.

How does ciprofloxacin pH affect excipient strategy?

Ciprofloxacin formulation design is constrained by the drug's amphoteric chemistry. Solubility changes with pH, and excessive alkalinity or acidity can affect tolerability, stability, or precipitation risk. An effective formulation must balance four variables:

1. Ciprofloxacin solubility.
2. Ocular comfort.
3. Chemical stability during shelf life.
4. Compatibility with the container-closure system.

Boric acid and sodium chloride provide a simple buffer-tonicity framework, while edetate disodium can bind trace metals that catalyze degradation. A developer seeking differentiation should avoid unnecessary excipient complexity. Each added surfactant, polymer, preservative, or viscosity enhancer increases the risk of irritation, extractables, compatibility problems, and regulatory comparability burdens.

Potential excipient platforms include:

Platform	Commercial rationale	Main development risk
Preservative-free aqueous solution	Supports sensitive-eye and frequent-use positioning	Sterility and multidose contamination control
Unit-dose ampoules	Removes preservative requirement and supports premium packaging	Higher packaging and distribution cost
Polymer-thickened solution	Extends ocular residence time	Blurring, drop size, and tolerability
In situ gel	Provides liquid administration with post-dose viscosity increase	More complex regulatory and performance package
Mucoadhesive formulation	May reduce dosing frequency	Ocular irritation and reproducibility
Lipid or emulsion system	May improve surface comfort	Ciprofloxacin solubilization and physical stability
Hydrocarbon-free ointment	May reduce visual disturbance	Vehicle development and manufacturing complexity

What formulation patents protect Ciloxan?

The original composition and formulation protection for Ciloxan is expired or commercially immaterial in the United States. Ciprofloxacin ophthalmic solution and ointment have been marketed for decades, and generic versions are widely available.

The relevant FDA products are associated with legacy New Drug Applications, including NDA 019847 for Ciloxan ophthalmic solution and NDA 020780 for Ciloxan ophthalmic ointment, according to FDA product records and labeling materials. These products do not present the profile of a recently launched medicine with meaningful Orange Book patent exclusivity.

IP category	Ciloxan position
Ciprofloxacin active ingredient	Off-patent
Conventional 0.3% ophthalmic solution	Generic competition established
Conventional 0.3% ophthalmic ointment	Generic competition established
Original formulation protection	Expired or no longer commercially significant
New delivery-system patents	Potentially available to new developers
Trademark	Ciloxan brand rights may remain jurisdiction- and owner-specific
Regulatory exclusivity	No current exclusivity expected to block conventional generic entry

A new developer could obtain patent protection for a redesigned delivery system, but a patent on a routine excipient substitution would face validity and obviousness pressure. Stronger claims would likely require a defined technical effect, such as materially extended residence time, improved stability, reduced dosing frequency, reduced ocular irritation, or a measurable improvement in clinical adherence.

What is the Orange Book status of Ciloxan?

Ciloxan is a legacy small-molecule ophthalmic product. Its conventional solution and ointment presentations are subject to established generic competition rather than active regulatory exclusivity.

For an ANDA applicant, the core pathway would generally involve demonstrating pharmaceutical equivalence and bioequivalence or other applicable FDA requirements for the reference listed drug. Ophthalmic products may require detailed control of:

• Active ingredient concentration.
• pH and osmolality.
• Sterility.
• Particulate matter.
• Drop size and delivered dose.
• Viscosity.
• Container-closure integrity.
• Preservative content, where applicable.
• Ointment uniformity and drug distribution.

The absence of a meaningful blocking patent estate reduces the importance of a Paragraph IV strategy for the conventional product. A Paragraph IV certification could still arise if a listed patent were relevant to a particular reference product, but the principal competitive barrier for Ciloxan is formulation execution and manufacturing economics, not patent clearance.

When does Ciloxan lose exclusivity?

Ciloxan has already lost its practical market exclusivity. The product was approved long enough ago that statutory new chemical entity exclusivity and the original patent term no longer control market entry.

The commercial timeline is therefore:

Milestone	Strategic impact
Original ciprofloxacin and ophthalmic product development	Created the initial product platform
FDA approval of Ciloxan solution and ointment	Established the reference products
Expiration of original patent and regulatory protections	Opened the market to generic competition
Current market	Commodity-like conventional drops with room for differentiated delivery

The principal opportunity is not to defend legacy Ciloxan exclusivity. It is to build new intellectual property around a differentiated ophthalmic product.

Which companies are challenging Ciloxan and competing with it?

Ciloxan competes with generic ciprofloxacin ophthalmic products rather than a single branded challenger. The market includes manufacturers of ciprofloxacin ophthalmic solution 0.3% and, in some jurisdictions, ophthalmic ointment products.

Competitive pressure comes from:

• Low-cost generic ophthalmic manufacturers.
• Contract manufacturers supplying private-label products.
• Branded or authorized generic channels.
• Combination antibiotic-steroid products.
• Alternative fluoroquinolones such as moxifloxacin and ofloxacin.
• Non-antibiotic ocular-surface products that compete for ophthalmology prescribing and pharmacy shelf space.

The conventional ciprofloxacin drop has limited differentiation. A new product would need either a meaningful clinical convenience benefit or a defensible channel strategy.

What excipient-led commercial opportunities exist for Ciloxan?

Preservative-free multidose delivery

Preservative-free multidose bottles are the most direct premium opportunity. A valve-based or airless container could deliver sterile drops without benzalkonium chloride or another conventional preservative. The commercial value would be strongest in:

• Repeated dosing for corneal ulcer treatment.
• Patients with ocular-surface disease.
• Postoperative or medically supervised use.
• Patients who cannot tolerate preserved drops.

The primary risks are container cost, contamination control, dose consistency, and regulatory validation.

Unit-dose preservative-free packaging

Unit-dose packaging is technically simpler than a preservative-free multidose bottle and can support hospital, surgical, and institutional channels. It creates a clear product distinction but may carry higher packaging, waste, and shipping costs.

A unit-dose product could also be positioned for emergency departments and ophthalmology practices where sterility and convenience are valued more than retail price.

Extended-retention aqueous drops

A viscosity-enhanced solution using a compatible polymer could reduce runoff and potentially improve ocular residence time. Candidate excipient classes include cellulose derivatives, povidone, polyvinyl alcohol, hyaluronic acid, and selected carbomers.

The product must avoid excessive viscosity. A formulation that causes blurred vision, stringiness, or poor drop formation can reduce adherence. A credible patent position would require data showing a specific balance of retention, tolerability, and delivered dose.

In situ gel systems

An in situ gel is administered as a low-viscosity liquid and increases viscosity after contact with the ocular surface. This approach can reduce administration burden while preserving drop-based dosing.

The main technical barriers are pH-triggered, temperature-triggered, or ion-triggered gelation; reproducible rheology; sterilization; and container compatibility. The regulatory burden is greater than for a simple generic solution, but so is the potential for differentiated claims.

Improved ointment vehicles

Ciloxan ointment uses mineral oil and white petrolatum, which provide retention but can cause temporary visual blur. A new semisolid vehicle could target:

• Faster clearance after administration.
• Lower visual disturbance.
• Improved spreadability.
• More uniform ciprofloxacin distribution.
• Better patient acceptance during waking hours.

A successful product would need to demonstrate that the new vehicle does not compromise antimicrobial exposure or ocular tolerability.

Combination products

A ciprofloxacin-dexamethasone product could address bacterial infection with inflammation, although it would compete with existing antibiotic-steroid products and face additional safety and labeling considerations. Other combinations could include lubricating or ocular-surface-supportive excipients, but the commercial and regulatory rationale must remain clinically clear.

Combination products may have stronger commercial value than a simple ciprofloxacin reformulation if they reduce the number of bottles or dosing steps. Their patentability would depend on the specific combination, formulation, dosing regimen, or demonstrated clinical effect.

What manufacturing and IP barriers affect a new Ciloxan competitor?

Manufacturing barriers are moderate for an aqueous solution and higher for advanced delivery systems.

A conventional solution requires validated sterile processing, aseptic filling, pH control, assay uniformity, particulate control, and container-closure integrity. An ointment requires controlled heating, mixing, sterilization or aseptic processing, and uniform drug dispersion.

A differentiated product adds:

• Polymer or emulsion stability.
• Sterilization compatibility.
• Extractables and leachables testing.
• Device-drug combination controls.
• Drop-size consistency.
• Long-term package performance.
• Human factors testing for novel delivery devices.

The strongest IP strategy would combine formulation, container, manufacturing process, and method-of-use claims. A single narrow composition claim is more vulnerable to design-around and invalidity challenges.

How does Ciloxan compare with competing ophthalmic antibiotics?

Product class	Main advantage	Main weakness	Competitive implication
Ciprofloxacin 0.3% solution	Established efficacy and low cost	Frequent dosing; mature generic market	Requires delivery differentiation
Ciprofloxacin ointment	Longer retention	Blurred vision and lower convenience	Niche opportunity for improved semisolid vehicles
Moxifloxacin solution	Convenient dosing and broad use	Higher cost; resistance considerations	Strong branded and generic competition
Ofloxacin solution	Established ophthalmic use	Less compelling differentiation	Price-driven competition
Antibiotic-steroid combinations	Addresses infection plus inflammation	Steroid safety and diagnostic limitations	Opportunity where combined therapy is clinically appropriate
Preservative-free antibiotic products	Better ocular-surface positioning	Packaging cost	Premium and institutional opportunity

Ciprofloxacin retains value in corneal ulcer management because of established clinical use and broad antibacterial activity. Its principal weakness is the commercial commoditization of the conventional dosage forms.

What generic launch risks exist?

Generic launch risk is high for a conventional 0.3% ophthalmic solution because multiple suppliers can compete on price and pharmacy access. A new entrant would face:

• Low average selling prices.
• Established generic substitutes.
• Limited brand loyalty.
• Retail substitution.
• Manufacturing and sterile-fill costs.
• Potential shortages or supply interruptions that can create temporary opportunities but are difficult to forecast.

Risk is lower for a differentiated preservative-free or extended-retention product if the product earns a distinct reimbursement code, hospital formulary position, or specialist recommendation. That opportunity depends on clinical evidence and reliable supply, not simply on a new excipient list.

What is the revenue exposure and commercial outlook?

Ciloxan's legacy revenue exposure is concentrated in branded or premium channels because standard ciprofloxacin products are heavily genericized. The larger opportunity is a reformulated product with a higher net price and a defensible clinical or packaging benefit.

The most attractive commercial sequence is:

1. Launch a preservative-free unit-dose or multidose product.
2. Target ophthalmology practices, hospitals, and ocular-surface specialists.
3. Generate comparative data on tolerability, retention, and adherence.
4. Protect the formulation and container system with coordinated patents.
5. Expand into combination or postoperative indications where permitted.

A low-cost generic strategy can succeed through manufacturing efficiency, but it offers limited strategic value unless the developer has a strong sterile ophthalmic platform or access to underserved markets.

Key Takeaways

• Ciloxan is a mature ciprofloxacin ophthalmic product with expired practical exclusivity.
• The solution uses boric acid, sodium chloride, edetate disodium, pH adjusters, and purified water.
• The ointment uses mineral oil and white petrolatum.
• Conventional Ciloxan formulations face substantial generic competition and limited patent protection.
• The strongest commercial opportunities are preservative-free delivery, unit-dose packaging, extended-retention drops, and improved ointment vehicles.
• New patent value will come from demonstrated technical effects, not routine excipient substitutions.
• The main barriers are sterile manufacturing, container performance, dose uniformity, ocular tolerability, and reimbursement.
• Ciloxan is a small-molecule antibiotic product and presents no biosimilar pathway issue.
• Paragraph IV litigation is less central than formulation differentiation and manufacturing execution.
• A premium reformulation has greater strategic potential than another conventional ciprofloxacin 0.3% generic.

FAQs

Can a preservative-free Ciloxan generic be patented?

A conventional preservative-free version is unlikely to receive broad protection solely because it omits a preservative. Patent strength would improve if the product uses a novel container, stabilizing system, multidose sterility mechanism, or demonstrated tolerability benefit.

Is ciprofloxacin ophthalmic ointment still commercially attractive?

It can be attractive in institutional and specialist channels, but conventional petrolatum-based ointment is mature. The strongest opportunity is a less blurring semisolid system with improved patient acceptance.

Does Ciloxan have biosimilar competition?

No. Ciloxan contains ciprofloxacin, a chemically synthesized small molecule. Competitors enter through generic-drug pathways rather than biosimilar approval.

What is the most defensible new product around Ciloxan?

A preservative-free multidose product supported by a proprietary container-closure system and validated sterility-control strategy offers one of the clearest opportunities for defensible differentiation.

Can a new excipient reduce Ciloxan dosing frequency?

Potentially, but the developer would need evidence that the excipient system increases ocular residence time or exposure without unacceptable blurring, irritation, altered drop size, or safety concerns.

References

1. Alcon Laboratories, Inc. (n.d.). Ciloxan ophthalmic solution 0.3% prescribing information. U.S. Food and Drug Administration labeling database.

2. Alcon Laboratories, Inc. (n.d.). Ciloxan ophthalmic ointment 0.3% prescribing information. U.S. Food and Drug Administration labeling database.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (1999). Guidance for industry: Ophthalmic drug products for topical administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ophthalmic-drug-products-topical-administration-chemistry-manufacturing-and-controls-guidance-industry